AR068917A1 - Productos quimioterapeuticos cristalinos derivados de indazol - Google Patents
Productos quimioterapeuticos cristalinos derivados de indazolInfo
- Publication number
- AR068917A1 AR068917A1 ARP080104543A ARP080104543A AR068917A1 AR 068917 A1 AR068917 A1 AR 068917A1 AR P080104543 A ARP080104543 A AR P080104543A AR P080104543 A ARP080104543 A AR P080104543A AR 068917 A1 AR068917 A1 AR 068917A1
- Authority
- AR
- Argentina
- Prior art keywords
- indazol
- approximately
- crystal
- methylphenyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forma cristalina 1 de N-[4-(3-amino-1H-indol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea hidrato, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento de pacientes que padecen una enfermedad para usarla contra el cáncer. Reivindicacion 1: Forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea hidrato caracterizada porque, cuando se mide a aproximadamente 25°C, con radiacion a 1,54178 L, se caracteriza por un patron de difraccion de polvo que tiene valores 2theta respectivos de aproximadamente 6,2°, 12,0°, 12,4°, 12,8°, 13,4°, 14,2°, 15,2°, 15,6°, 16,2° y 19,7°. Reivindicacion 2: Una formulacion caracterizada porque comprende un excipiente y la forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea hidrato que, cuando se mide a aproximadamente 25°C con radiacion a 1,54178 L, se caracteriza por un patron de difraccion de polvo que tiene valores 2theta respectivos de aproximadamente 6,2°, 12,0°, 12,4°, 12,8°, 13,4°, 14,2°, 15,2°, 15,6°, 16,2° y 19,7°.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98123607P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068917A1 true AR068917A1 (es) | 2009-12-16 |
Family
ID=40090209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104543A AR068917A1 (es) | 2007-10-19 | 2008-10-17 | Productos quimioterapeuticos cristalinos derivados de indazol |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7947843B2 (es) |
| EP (1) | EP2195298B1 (es) |
| JP (1) | JP5517940B2 (es) |
| KR (1) | KR20100085116A (es) |
| CN (1) | CN101827822B (es) |
| AR (1) | AR068917A1 (es) |
| AU (1) | AU2008312529A1 (es) |
| BR (1) | BRPI0818065A8 (es) |
| CA (1) | CA2699352C (es) |
| CL (1) | CL2008003090A1 (es) |
| CO (1) | CO6280481A2 (es) |
| CR (1) | CR11388A (es) |
| DO (1) | DOP2010000115A (es) |
| EC (1) | ECSP10010188A (es) |
| ES (1) | ES2460951T3 (es) |
| MX (1) | MX2010004286A (es) |
| PA (1) | PA8800201A1 (es) |
| PE (1) | PE20091385A1 (es) |
| RU (1) | RU2010119928A (es) |
| SG (1) | SG185327A1 (es) |
| TW (1) | TW200934485A (es) |
| UA (1) | UA99746C2 (es) |
| UY (1) | UY31407A1 (es) |
| WO (1) | WO2009052226A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947843B2 (en) * | 2007-10-19 | 2011-05-24 | Abbott Laboratories | Crystalline chemotherapeutic |
| US8759538B1 (en) | 2013-06-13 | 2014-06-24 | Abbvie Inc. | Crystalline chemotherapeutic |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| NZ543614A (en) * | 2003-05-22 | 2009-09-25 | Abbott Lab | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| EP1925676A4 (en) * | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| CA2626579A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20100143459A1 (en) * | 2006-11-09 | 2010-06-10 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US7947843B2 (en) * | 2007-10-19 | 2011-05-24 | Abbott Laboratories | Crystalline chemotherapeutic |
-
2008
- 2008-10-15 US US12/251,879 patent/US7947843B2/en not_active Expired - Fee Related
- 2008-10-16 SG SG2012078291A patent/SG185327A1/en unknown
- 2008-10-16 BR BRPI0818065A patent/BRPI0818065A8/pt not_active IP Right Cessation
- 2008-10-16 KR KR1020107010993A patent/KR20100085116A/ko not_active Application Discontinuation
- 2008-10-16 AU AU2008312529A patent/AU2008312529A1/en not_active Abandoned
- 2008-10-16 JP JP2010530090A patent/JP5517940B2/ja not_active Expired - Fee Related
- 2008-10-16 MX MX2010004286A patent/MX2010004286A/es active IP Right Grant
- 2008-10-16 UA UAA201006033A patent/UA99746C2/ru unknown
- 2008-10-16 CA CA2699352A patent/CA2699352C/en not_active Expired - Fee Related
- 2008-10-16 EP EP08839857.3A patent/EP2195298B1/en active Active
- 2008-10-16 CN CN2008801119044A patent/CN101827822B/zh not_active Expired - Fee Related
- 2008-10-16 RU RU2010119928/04A patent/RU2010119928A/ru not_active Application Discontinuation
- 2008-10-16 WO PCT/US2008/080061 patent/WO2009052226A1/en active Application Filing
- 2008-10-16 ES ES08839857.3T patent/ES2460951T3/es active Active
- 2008-10-17 AR ARP080104543A patent/AR068917A1/es unknown
- 2008-10-17 TW TW097140034A patent/TW200934485A/zh unknown
- 2008-10-17 UY UY31407A patent/UY31407A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003090A patent/CL2008003090A1/es unknown
- 2008-10-17 PE PE2008001784A patent/PE20091385A1/es not_active Application Discontinuation
- 2008-10-17 PA PA20088800201A patent/PA8800201A1/es unknown
-
2010
- 2010-04-16 DO DO2010000115A patent/DOP2010000115A/es unknown
- 2010-04-23 CR CR11388A patent/CR11388A/es unknown
- 2010-04-27 CO CO10049264A patent/CO6280481A2/es not_active Application Discontinuation
- 2010-05-18 EC EC2010010188A patent/ECSP10010188A/es unknown
-
2011
- 2011-04-18 US US13/088,869 patent/US8486988B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010119928A (ru) | 2011-11-27 |
| PA8800201A1 (es) | 2009-05-15 |
| JP5517940B2 (ja) | 2014-06-11 |
| US7947843B2 (en) | 2011-05-24 |
| US20090118344A1 (en) | 2009-05-07 |
| CN101827822B (zh) | 2013-06-19 |
| CR11388A (es) | 2010-10-05 |
| AU2008312529A1 (en) | 2009-04-23 |
| TW200934485A (en) | 2009-08-16 |
| WO2009052226A1 (en) | 2009-04-23 |
| EP2195298B1 (en) | 2014-02-19 |
| US8486988B2 (en) | 2013-07-16 |
| ECSP10010188A (es) | 2010-06-29 |
| ES2460951T3 (es) | 2014-05-16 |
| CL2008003090A1 (es) | 2009-11-27 |
| KR20100085116A (ko) | 2010-07-28 |
| DOP2010000115A (es) | 2010-10-15 |
| BRPI0818065A8 (pt) | 2016-03-08 |
| CA2699352C (en) | 2016-06-21 |
| EP2195298A1 (en) | 2010-06-16 |
| CN101827822A (zh) | 2010-09-08 |
| CO6280481A2 (es) | 2011-05-20 |
| UA99746C2 (ru) | 2012-09-25 |
| BRPI0818065A2 (pt) | 2015-03-31 |
| PE20091385A1 (es) | 2009-11-12 |
| JP2011500705A (ja) | 2011-01-06 |
| MX2010004286A (es) | 2010-04-30 |
| UY31407A1 (es) | 2009-05-29 |
| US20110196010A1 (en) | 2011-08-11 |
| SG185327A1 (en) | 2012-11-29 |
| CA2699352A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121017T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| TW200637562A (en) | Anti-cancer agent containing α-α-α-trifluorothymidine and thymidine phosphorylase inhibitor in combination | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| ECSP067068A (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA | |
| UY29405A1 (es) | Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la continen. | |
| AR062402A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel | |
| PH12019502334A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| CO6270221A2 (es) | "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". | |
| AR068917A1 (es) | Productos quimioterapeuticos cristalinos derivados de indazol | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| CY1113164T1 (el) | Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη | |
| DOP2010000113A (es) | Productos quimioterapeuticos cristalinos | |
| AR066550A1 (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa | |
| SG148119A1 (en) | Morusin a, the preparing method and the use thereof | |
| TH104745B (th) | สารทางเคมีบำบัดที่เป็นผลึก | |
| TH104745A (th) | สารทางเคมีบำบัดที่เป็นผลึก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |